PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
48.17
+2.90 (6.41%)
At close: Aug 13, 2025, 4:00 PM
47.51
-0.66 (-1.37%)
Pre-market: Aug 14, 2025, 8:53 AM EDT
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $178.88M in the quarter ending June 30, 2025, a decrease of -4.19%. This brings the company's revenue in the last twelve months to $1.76B, up 96.00% year-over-year. In the year 2024, PTC Therapeutics had annual revenue of $806.78M, down -13.97%.
Revenue (ttm)
$1.76B
Revenue Growth
+96.00%
P/S Ratio
2.12
Revenue / Employee
$1,879,584
Employees
939
Market Cap
3.83B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 806.78M | -131.04M | -13.97% |
Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PTCT News
- 5 days ago - PTC Therapeutics, Inc. (PTCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - PRNewsWire
- 15 days ago - Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics - Benzinga
- 15 days ago - These Analysts Increase Their Forecasts On PTC Therapeutics - Benzinga
- 16 days ago - US FDA approves PTC Therapeutics' metabolic disorder drug - Reuters
- 16 days ago - PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - PRNewsWire
- 23 days ago - PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire